Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Blood (2023) 142 (Supplement 1): 6907.

https://doi.org/10.1182/blood-2023-181999

Published: 2023

Journal Articles

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4889.

https://doi.org/10.1182/blood-2023-187240

Published: 2023

Journal Articles

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Blood (2023) 142 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2023-181997

Published: 2023

Journal Articles

Axicabtagene Ciloleucel in Patients Aged 75 and Older: A Retrospective Cohort Study

Neela Easwar, Joshua Fein, Michelle S Pasciolla, Rachel Abramova, Tsiporah B. Shore, Samuel Yamshon

Blood (2023) 142 (Supplement 1): 6318.

https://doi.org/10.1182/blood-2023-178187

Published: 2023

Journal Articles

Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT

Joshua Fein, Myriam Labopin, MD, Roni Shouval, MD PhD, Gerard Socie, MD PhD, Jürgen Finke, MD, Jan J Cornelissen, MD PhD, Ram Malladi, Maija Itälä-Remes, MD PhD, Patrice Chevallier, MD, Kim H. Orchard, MBBS,PhDFRCP,FRCPath, Donald Bunjes, MD, Mahmoud Aljurf, MD, Marie Thérèse Rubio, MD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 203.

https://doi.org/10.1182/blood-2018-99-113296

Published: 2018

Journal Articles

Determinants for Oral Mucositis in Allogeneic Hematopoietic Stem Cell Transplantation: Prospective Evaluation and Risk Analysis

Roni Shouval, Liza Kouniavsky, Joshua Fein, Ivetta Danylesko, Arie Apel, MD, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 3239.

https://doi.org/10.1182/blood.V130.Suppl_1.3239.3239

Published: 2017

Journal Articles

Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Benjamin L. Lampson, MD PhD, Haesook T Kim, PhD, Matthew S. Davids, MD, Jeremy S. Abramson, MD MMSc, Arnold S. Freedman, MD, Caron A. Jacobson, MD, Philippe Armand, MD PhD, Robin M. Joyce, MD, Jon E. Arnason, MD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, Samantha Huang, Joshua Fein, John Hanna, Stacey Marie Fernandes, BS, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 1734.

https://doi.org/10.1182/blood.V130.Suppl_1.1734.1734

Published: 2017

Journal Articles

Comorbidity-Driven Risk across Preparative Regimens for Allogeneic Hematopoietic Stem Cell Transplantation

Joshua Fein, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Nadav Furie, MD, Arie Apel, MD, Avichai Shimoni, MD, Arnon Nagler, MD, Roni Shouval

Blood (2017) 130 (Supplement 1): 1933.

https://doi.org/10.1182/blood.V130.Suppl_1.1933.1933

Published: 2017

Journal Articles

Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT

Roni Shouval, Joshua Fein, Myriam Labopin, MD, Nicolaus Kröger, Rafael F Duarte, MD PhD FRCP, Peter Bader, MD PhD, Bonini Chiara, MD, Jurgen Kuball, MD, Grzegorz Basak, MD PhD, Carlo Dufour, MD, Arjan Lankester, MD PhD, Silvia Montoto, John A Snowden, MD, Jan Styczynski, PhD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 668.

https://doi.org/10.1182/blood.V130.Suppl_1.668.668

Published: 2017

Journal Articles

Prediction of Allogeneic Stem Cell Transplantation Mortality in Patients with Acute Leukemia (AL) Using the AL- European Society for Blood and Marrow Transplantation (EBMT) Risk Score in the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) Data Set: A Study on Behalf of the AL Working Party (ALWP) of the EBMT and GITMO

Roni Shouval, MD, Francesca Bonifazi, MD, Joshua Fein, Cristina Boschini, BSc, Elena Oldani, BiolSc, Myriam Labopin, Roberto Raimondi, MD, Osamah Dabash, MD, Ron Unger, PhD, Mohamad Mohty, MD PhD, Alessandro Rambaldi, MD, Arnon Nagler

Blood (2016) 128 (22): 989.

https://doi.org/10.1182/blood.V128.22.989.989

Published: 2016

Journal Articles

Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord

Blood (2016) 128 (22): 1169.

https://doi.org/10.1182/blood.V128.22.1169.1169

Published: 2016

Journal Articles

The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT)

Roni Shouval, MD, Joshua Fein, Myriam Labopin, Nicolaus Kroger, MD PhD, Rafael F. Duarte, MD PhD, Peter Bader, MD, Chiara Bonini, MD, Peter Dreger, MD, Carlo DuFour, MD, Andrew Gennery, MD, Jurgen Kuball, MD PhD, Francesco Lanza, MD, Silvia Montoto, MD, Emmanuelle Polge, John A Snowden, Jan Styczynski, MD PhD, Anna Sureda, MD PhD, Mohamad Mohty, MD PhD, Arnon Nagler

Blood (2016) 128 (22): 988.

https://doi.org/10.1182/blood.V128.22.988.988

Published: 2016

Journal Articles

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Benjamin L. Lampson, Siddha N. Kasar, Tiago R. Matos, Elizabeth A. Morgan, Laura Rassenti, Matthew S. Davids, David C. Fisher, Arnold S. Freedman, Caron A. Jacobson, Philippe Armand, Jeremy S. Abramson, Jon E. Arnason, Thomas J. Kipps, Joshua Fein, Stacey Fernandes, John Hanna, Jerome Ritz, Haesook T. Kim, Jennifer R. Brown

Blood (2016) 128 (2): 195–203.

https://doi.org/10.1182/blood-2016-03-707133

Published: 2016

Includes: Supplemental data

Journal Articles

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Mary Ann Anderson, Jing Deng, John F. Seymour, Constantine Tam, Su Young Kim, Joshua Fein, Lijian Yu, Jennifer R. Brown, David Westerman, Eric G. Si, Ian J. Majewski, David Segal, Sari L. Heitner Enschede, David C. S. Huang, Matthew S. Davids, Anthony Letai, Andrew W. Roberts

Blood (2016) 127 (25): 3215–3224.

https://doi.org/10.1182/blood-2016-01-688796

Published: 2016

Includes: Supplemental data

Journal Articles

Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities

Benjamin L Lampson, MD PhD, Tiago Matos, MD MSc, Haesook T. Kim, PhD, Siddha Kasar, PhD, Elizabeth A. Morgan, MD, Masahiro Hirakawa, MD PhD, Joshua Fein, Stacey M. Fernandes, Jerome Ritz, MD, Jennifer R. Brown, MD PhD

Blood (2015) 126 (23): 497.

https://doi.org/10.1182/blood.V126.23.497.497

Published: 2015

NARROW

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Axicabtagene Ciloleucel in Patients Aged 75 and Older: A Retrospective Cohort Study

Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT

Determinants for Oral Mucositis in Allogeneic Hematopoietic Stem Cell Transplantation: Prospective Evaluation and Risk Analysis

Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Comorbidity-Driven Risk across Preparative Regimens for Allogeneic Hematopoietic Stem Cell Transplantation

Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT

Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord

The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT)

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only